Navigation Links
Labrys Biologics Initiates Two Phase 2 Studies of LBR-101 for the Prevention of Chronic and Episodic Migraine
Date:1/8/2014

mean change from baseline in the number of migraine days after 12 weeks of treatment. Topline data are expected in late 2014 to early 2015.

About LBR-101
LBR-101 (formerly RN-307) is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a well validated target in migraine. LBR-101 was originally discovered and developed by Rinat Pharmaceuticals, which was acquired by Pfizer in 2006.  LBR-101 has successfully completed Phase 1 trials with active drug being given to 106 volunteers, results of which were published in Cephalalgia, the official journal of the International Headache Society, in December 2013. Both IV and subcutaneous administrations were extremely well tolerated. LBR-101 exhibited a long terminal half-life ranging from 40 to 48 days, which supports once-monthly dosing. Most treatment related adverse events were mild, transient and resolved spontaneously. The most common TEAEs reported were nasopharyngitis, gastroenteritis and back pain. A maximum tolerated dose has not been identified. LBR-101 was not associated with any clinically relevant patterns of change in vital signs, ECG parameters, or laboratory findings.

LBR-101's long half-life, target specificity and favorable pharmacokinetic profiles, including lack of hepatic metabolism and limited potential for drug interaction may address substantial unmet needs for the prevention of frequent episodic migraines and chronic migraines, a market estimated to be more than 10 million patients in the United States. Proof of efficacy was obtained for several CGRP antagonists in the symptomatic (acute) relief of migraine, yet prophylactic use of those small molecules has been limited by liver toxicity or formulation difficulties. There is only one FDA approved drug for the prevention of chronic migraine (onabotulinumtoxin A), demonstrating the significant
'/>"/>

SOURCE Labrys Biologics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orthobiologics Market (Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others) is Expected to Reach USD 5,519.9 Million Globally in 2019: Transparency Market Research
2. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
3. Crescendo Biologics Raises £17.5M ($28M) in Series A Financing
4. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
5. Synthetic Biologics Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th
6. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
7. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
8. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
9. Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety
10. Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th
11. Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
(Date:9/17/2014)... 17 2014 IBM (NYSE: IBM ) ... IBM technical computing and storage technology to accelerate ... These services deliver critically important information to help ... unique cancer, which could lead to better health ... in general. Today, optimal cancer care ...
(Date:9/17/2014)... , September 17, 2014 ... to congratulate Biocartis commitment in shipping its first ... long-time investor in Biocartis as part of Debiopharm ... fully automated, real-time PCR based molecular diagnostics system, ... access to clinical molecular diagnostic information, anywhere and ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 2Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 4Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument 2
... - NanoViricides,Inc. (Pink Sheets: NNVC) discussed today the ... presented along with the,successful BSL3 in vitro studies ... Annual Symposium of the Pan American Society for ... (Pan American Society,for Clinical Virology (PASCV): Clinical Virology ...
... and Symptom Severity; New,Resources for Patients, Parents, WASHINGTON, ... today by the National Consumers League shows that ... days. Four in,ten asthma sufferers understand asthma medication ... recent the diagnosis, the less,knowledgeable adult patients tend ...
Cached Medicine Technology:Global Rabies Treatment May be Possible with NanoViricides Drugs 2New Survey Finds Troubling Data on American Asthma Sufferers 2New Survey Finds Troubling Data on American Asthma Sufferers 3New Survey Finds Troubling Data on American Asthma Sufferers 4New Survey Finds Troubling Data on American Asthma Sufferers 5New Survey Finds Troubling Data on American Asthma Sufferers 6
(Date:9/17/2014)... Thomas A. Sellers, Ph.D., M.P.H., Jong Park, Ph.D. and Hui-Yi ... that influence the risk for developing prostate cancer, according to ... , Prostate cancer is the most common non-skin cancer in ... with the disease in his lifetime. Family history is the ... brother or father with prostate cancer is twice as likely ...
(Date:9/17/2014)... People with facial paralysis are perceived as being ... universal language of facial expression, a new study from ... The findings highlight the important role the face plays ... prejudice against those with facial paralysis because of their ... in the College of Liberal Arts at Oregon State ...
(Date:9/17/2014)... Tools4ever, the market leader ... and Boston Software Systems, leader in healthcare ... Under the agreement, Tools4ever will use ... within its identity and password management solutions. ... automation platforms that streamline complex processes and ...
(Date:9/17/2014)... September 17, 2014. Kessler Foundation is the recipient ... the International Progressive Multiple Sclerosis (MS) Alliance. ... Traumatic Brain Injury Research, is principal investigator of ... of cognitive rehabilitation in individuals with progressive multiple ... grants awarded by the Alliance to investigators in ...
(Date:9/17/2014)... Gerontological Society of America (GSA) invites all journalists ... the country,s largest interdisciplinary conference in the field ... Washington, DC. Media representatives may register free of charge. ... the five-day gathering at the Walter E. Washington Convention ... 2014 is "Making Connections: From Cells to Societies" and ...
Breaking Medicine News(10 mins):Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Kessler Foundation receives first-round grant from International Progressive Multiple Sclerosis Alliance 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2
... ... Innovation and Growth , ... (PRWEB) June 21, 2010 -- DKI Direct ( http://www.dkidirect.com ), a leading Patient ... Chief Marketing Officer. Lewis will lead and build the marketing efforts for both existing ...
... viral for bacterial infections, review found , MONDAY, ... one who can,t always tell if your child has ... for antibiotics: Pediatricians say this is the most common ... Other common missed or mistaken diagnoses include those involving ...
... and cost-effective when targeted to high-risk patients, according ... the official journal of the American Gastroenterological Association ... be excessively costly or even harmful. "Surveillance ... that has the potential to decrease the burden ...
... something is due to our genes and how much is ... academic journal Addiction shows that the case is ... drugs, for two related reasons. First, a young woman ... to choose friends who smoke, drink, or use drugs, thereby ...
... in the journal Addiction reveals that drunkenness increases ... a strong inclination to suppress anger. The two ... reduces the risk of drawing erroneous conclusions about cause and ... of evidence suggesting that drinking may in fact inflict physical ...
... ... because of a small number of adverse event reports received by the FDA from users ... and its safety if used as directed. , ... (PRWEB) June 21, 2010 -- EphedrineHydrochloride.com is pleased to announce ...
Cached Medicine News:Health News:DKI Direct Appoints Greg Lewis as Chief Marketing Officer 2Health News:More Than Half of Pediatricians Make Diagnostic Errors: Survey 2Health News:More Than Half of Pediatricians Make Diagnostic Errors: Survey 3Health News:Surveillance colonoscopy should be targeted to high-risk patients 2Health News:New research shows peer drug use may increase an individual's genetic tendency to use drugs 2Health News:Ephedrine Hydrochloride.com Launches Review Site Examining Ephedrine HCL & Ephedra Based Diet Pills 2
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
For the qualitative detection of Wuchereria bancrofti antigen in whole blood, serum and plasma specimens...
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
Medicine Products: